Atrasentan for proteinuria

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Sep 2026: Trial registered, NCT07850752
  2. 11 Nov 2026: Trial started, NCT07850752

The trials

NCT07850752: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy

State
Under way
Phase
Phase 3
People
340 planned
Started
11 Nov 2026
Primary completion
17 Sep 2028
Arms
zigakibart + atrasentan
Results
None posted
  1. 30 Sep 2026: Trial registered
  2. 11 Nov 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.